Biophytis produces three exhibitions of the oral posters and one in the 2019 International Conference on Criminal Investigation and Sarcophenia


PARIS, February 18, 2019 (GLOBE NEWSWIRE) – Biophytis SA (Euronext Growth Paris: ALBPS), a technological level biotechnology company, which focuses on the development of a new age-related disease system. The 2019 International Conference on Criminal Investigation and Sarcopenia (ICFSR 2019) is held from 20 February to 22, 2019 in Miami Beach, FL. Its Company gives detailed information about the main clinical candidate of its drugs, Sarconeos (BIO101), and including its history and a specific device that focuses on the MAS receptor for its & # 39; Retention of muscle work in muscle prevention problems. In addition, its Company will send the clinical trial design of their SARA Level 2 survey of Sarconeos (BIO101) in sarcophenia.

Stanislas Veillet, Ph.D., Biophytis Chief Executive, said, "We are pleased to be elected for three live shows and posters at ICFSR 2019. We are looking forward to sharing Sarconeos (BIO101) ability for the treatment of sarcopenia and other muscular dystrophies with international clinics and scientists from industry and academia. We believe that Sarconeos (BIO101) is one of the most economical drug candidates in clinical development for the treatment of sarcopenia, bad conversion of aiatric muscles and medication is not allowed at present. "

Details of the exhibitions are as follows:

Title: Sarconeos (API BIO101) focuses on a receptor Mas inside the ribbon angiotensin system protection bracket and its; Determining efficiencies in different models of muscle wear.
Presenter: Pierre Dilda, Ph.D.
Date / time: Wednesday, February 20, 2019 / 5:30 pm EST
Further Information: Live Communication 10
Title: Infective Stioid Hormonides such as Human Medicine: Application to Sarcopenia and Muscle Dystrophies.
Presenter: Stanislas Veillet, Ph.D.
Date / time: Thursday, February 21, 2019/12: 25pm EST
Further Information: A Business Showcase at the Food Industry Company held by Biophytis
Title: Designing a clinical program for BIO101, Mas receptor activist for extracting age-related sarcopenia.
Presenter: Waly Dioh, Ph.D.
Date / time: Thursday, February 21 2019 / 12:25 pm EST
Further Information: A Business Showcase at the Food Industry Company held by Biophytis
Title: Valuation of the safety and effectiveness of BIO101, a new research drug for sarcopenia: a double-blind clinical trial, a randomly controlled control space.
Presenter: Waly Dioh, Ph.D.
Date / time: Thursday, February 21, 2019
Further Information: Poster: Clinical Tests and Illness P78

About Biophytis
Biophytis is a biotechnology of biotechnology company, which aims to develop a new and emerging dynamic system. slowing down the processes of bleeding and developing active patient outcomes. suffering from age-related disease. Our practical approach is to focus on biological sustainability pathways; protective attack and influence the biological diversity impacts of the biological; leading to age-related diseases. The most drug-friendly candidate, Sarconeos (BIO101), is for the treatment of neuromuscular diseases, including sheltered excellence of sarcopenia and Duchenne. Our second drug applicant, Macuneos (BIO201), is a remedy for retinopathies, including dry age-related macular illness (AMD) and Stargardt disease. Biophytis is based in Paris, France and Cambridge, Massachusetts. For more information, visit www.biophytis.comSouth Westerly

BIOPHYTIS is listed on the Euronext Fàs market at Euronext Paris (ALBPS; ISIN: FR0012816825).

Follow us on Twitter @biophytis

BIOPHYTIS is eligible for the SMEs scheme

This press release includes special promotional statements. Although the Company believes that its expectations are based on reasonable responses, these positive statements are subject to many dangers and uncertainty, which can cause very different from those what was expected. For a discussion on risk and uncertainty that may cause different reasons from the statements that are forward looking, financial position, performance or performance is a. Company, look at the Risk Factors section ("Facteurs de Risque") of the Registration Prospectus when Company shares are included for trading on the # 39; Regulated Euronext Fàs Euronext Paris market incorporated by the AMF, which is available on the AMF website ( or at www.biophytis.comSouth Westerly

This press release and the information included here is not a sale offer or application for a bid to purchase or enter Biophytis shares in any country. Items in this press may be a # 39; Introducing statements that include risks and uncertainty. The real products of the Company could make a great difference to those who had been able to do so. Expectations in these statements are due to a number of risk factors defined in the Company's pre-vision. This press release was produced in French and English. If there is any difference between the two texts, the French language version will be involved.

Chief Finance Officer
[email protected]
Telephone: +1 (646) 479-8060

Contact US Media
LifeSci Public Relations
Cherilyn CECCHINI, M.D.
[email protected]
Telephone: +1 (646) 876-5196

Contact Media Media
Dewe Rogerson's Connector
Laurence BAULT / Antoine DENRY
[email protected]
[email protected]
Telephone: +33 (0) 1 53 32 84 78
Mob: +33 (0) 6 64 12 53 61

Source link